IP Library Granted Patent US 9,084,841
Granted Patent B2
US 9,084,841 · App. 14/621,893 · Granted Jul 21, 2015

Compositions and methods for preventing cardiac arrhythmia

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,084,841
App. No.
14/621,893
Granted
Jul 21, 2015
Kind
B2
Abstract

Disclosed herein are compositions and methods for treating or preventing cardiac arrhythmia in a subject.

Claims (6)

1. A method of treating atrial fibrillation in a subject, comprising:

providing an extracellular matrix (ECM) composition comprising ECM from a mammalian tissue source comprising acellular basement membrane, said ECM composition further comprising a statin and an exogenously added growth factor comprising transforming growth factor-β (TGF-β), said statin and growth factor being linked to said ECM, wherein, when said ECM composition is administered to damaged myocardium tissue of said subject, said statin and growth factor interact with said ECM to modulate inflammation of said myocardium tissue and induce remodeling of cardiac tissue, whereby said ECM composition modulates electrical activity in the heart of said subject; and

delivering said ECM composition directly to said damaged myocardium tissue of said subject, wherein said ECM composition reduces incidence of atrial fibrillation.

2. The method of claim 1 , wherein said mammalian tissue source comprises a tissue source selected from the group consisting of mammalian tunica propria, tunica submucosa, tunica muscularis and tunica serosa.

3. The method of claim 1 , wherein said statin is selected from the group consisting of lovastatin, simvastatin, atorvastatin, fluvastatin, pravastatin, rosuvastatin, cerivastatin and pitavastatin.

4. The method of claim 1 , wherein said ECM composition further comprises an embryonic stem cell.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2025
From: CORMATRIX CARDIOVASCULAR, INC.
To: CORVIVO CARDIOVASCULAR, INC.
Reel/Frame 070482/0001 →
CHANGE OF NAME Recorded Sep 15, 2023
From: AZIYO BIOLOGICS, INC.
To: ELUTIA INC.
Reel/Frame 064923/0361 →
CHANGE OF NAME Recorded Sep 15, 2023
From: AZIYO MED, LLC
To: ELUTIA MED LLC
Reel/Frame 064923/0704 →
RELEASE OF SECURITY INTEREST Recorded Aug 12, 2022
From: AZIYO BIOLOGICS, INC.; AZIYO MED, LLC
To: MIDCAP FUNDING IV TRUST
Reel/Frame 061164/0532 →
RELEASE OF SECURITY INTEREST Recorded Aug 12, 2022
From: AZIYO BIOLOGICS, INC.; AZIYO MED, LLC
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061161/0001 →
RELEASE OF SECURITY INTEREST Recorded Jun 2, 2017
From: MIDCAP FINANCIAL TRUST
To: CORMATRIX CARDIOVASCULAR, INC.
Reel/Frame 042669/0559 →
SECURITY INTEREST Recorded Sep 30, 2015
From: CORMATRIX CARDIOVASCULAR, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 036732/0103 →